ARTICLE 1Exclusive Licensing Agreement • November 21st, 2005 • Zann Corp • Pharmaceutical preparations
Exhibit 10.4 EXCLUSIVE LICENSING AGREEMENT BETWEEN: INSTITUTE OF MATERIA MEDICA Chinese Academy of Medical Sciences & Peking Union Medical College 1 Xian Nong Tan Street, Beijing 100050, China AND: BEIJING UNION PHARMACEUTICAL FACTORY 1 Xian Nong Tan...Exclusive Licensing Agreement • September 12th, 2006 • Sinopharm Inc • Pharmaceutical preparations
EXHIBIT 10.19 EXCLUSIVE LICENSING AGREEMENT This Agreement made effective as of this 24th day of June, 1999, by and between Ingen Technologies, Inc., a Nevada Corporation doing business in the State of California, further referred as the ("Company")...Exclusive Licensing Agreement • March 3rd, 2008 • Ingen Technologies, Inc. • Miscellaneous manufacturing industries • California
EXCLUSIVE LICENSING AGREEMENT FOR CERTAIN ASSETS OF SMLX, INC., AND ANY SUBSIDIARY THEREOF INTO WHICH SUCH ASSETS ARE TRANSFERRED OR PLACED AND PURCHASE OPTION AGREEMENT This agreement dated as of the 13th day of April, 1999, among VECTOR MEDICAL...Exclusive Licensing Agreement • May 28th, 1999 • SMLX Technologies Inc • Services-personal services • Florida
Exclusive licensing agreementExclusive Licensing Agreement • July 22nd, 2020 • England and Wales
Gaming of Ground Floor, 15 Heritage Park, Hayes Way, Cannock, Staffs, WS11 7LT and the “Assignor” (Full name as provided in your Submission Form), that states:
Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog...Exclusive Licensing Agreement • January 14th, 2015 • Intrexon Corp • Services-commercial physical & biological research
GERMANTOWN, Md., BOSTON, Ma., and HOUSTON, Tx., January 13, 2015 – Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ:ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
Komatsu renew exclusive simulator agreement with Immersive TechnologiesExclusive Licensing Agreement • May 30th, 2011
LONGPORT, INC. 791 S. CHESTER ROAD SWARTHMORE, PA 19081Exclusive Licensing Agreement • May 11th, 1998 • Longport Inc • Wholesale-medical, dental & hospital equipment & supplies
DURATION: THREE YEARS: 180 DAY INTERVALS, THE AGREEMENT CAN BE CANCELLED BY EITHER PARTY. *RENEWABLE AFTER THREE YEARS FOR SAME AMOUNT. *CHANGES AGREEABLE WITH BOTH PARTIES *CANCELLATION FOR JUST CAUSE GIVEN BY SIXTY (60) DAYS WRITTEN NOTICE. NOTIFICATION BY CERTIFIED OR REGISTERED MAIL.
AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian CountriesExclusive Licensing Agreement • April 3rd, 2008 • Amdl Inc • Surgical & medical instruments & apparatus
TUSTIN, Calif., April 3, 2008 — AMDL, Inc. (Amex: ADL — News), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc. (“JPI”), AMDL engages in the research, development, manufacture, and marketing of diagnostic products. Today, AMDL announced that it has entered into an exclusive sublicense (subject to certain terms and conditions) agreement with MyGene International, Inc. (“MGI,” USA) for the MyGene HPV Chip Kit, a diagnostic product for in-vitro genotype testing in women of the Human Papilloma Virus (HPV). The agreement between MGI and AMDL is an exclusive sublicense to use the patents, trademark, and technology in manufacturing, promoting, marketing, distributing, and selling the MyGene HPV Test Kit in the countries of China (including Hong Kong), Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam. MGI owns an exclus
TBG Diagnostics, Medigen and National Taiwan University Hospital enter Exclusive Licensing Agreement for the Development and Distribution of Patented Product for Evaluation of Adverse Reaction in Antithyroid Drug.Exclusive Licensing Agreement • November 5th, 2021
Melbourne, Australia, 13 March 2017. The Board of TBG Diagnostics Limited (ASX: TDL) (the Company or TBG) is pleased to announce that in association with Taiwan based biopharmaceutical company, Medigen Corp., it has entered into an Exclusive Licensing Agreement with the National Taiwan University Hospital (NTUH) for development and distribution of a patented product that is designed to evaluate adverse reactions to antithyroid drugs. With the signing of the Agreement, the TBG Medigen partnership will obtain the worldwide exclusive right to develop and distribute an invitro diagnostic (IVD) product that can identify and prevent patients suffering Grave’s Disease (GD) from developing further life-threatening agranulocytosis after taking Thionamide drugs.
Exclusive Licensing Agreement between The University of Washington and Lumera Corporation Effectively Dated October 16, 2000 List of ExhibitsExclusive Licensing Agreement • April 2nd, 2001 • Microvision Inc • Electronic components, nec • Washington
This Exclusive Licensing Agreement is entered into by and between the University of Washington (the “University”) and Lumera, Inc., a Washington corporation (the “Licensee”) as of the Effective Date, subject to the following terms and conditions.
Exclusive Licensing Agreement with Meitu NetworksExclusive Licensing Agreement • September 2nd, 2014
This announcement is made by Feiyu Technology International Company Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to the Rule 13.09(2) of the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).
First Addendum Exclusive Licensing AgreementExclusive Licensing Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This First Addendum to the Agreement (as defined below) is made and entered into between Licensor and Licensee as of the Effective Date of the Agreement.
Indian Institute of Food Processing Technology Ministry of Food Processing Industries, Government of IndiaExclusive Licensing Agreement • May 27th, 2020
Sub: Invitation for Expression of Interest (EoI) for Exclusive Licensing Agreement to Manufacture and Supply of Equipment/Gadgets/ Technologies Developed by MoFPI - IIFPT – Extension of Last Date for Submission of EoI Documents – Reg.
EXCLUSIVE LICENSING AGREEMENTExclusive Licensing Agreement • December 14th, 2020 • California
This Exclusive Licensing Agreement (“Agreement”) is by and between LDRLY (Technologies) Inc, a corporation formed under the laws of the Province of British Columbia, with a principal place of business at 104 Front Street, Nanaimo, BC V9R 5H7, Canada (“LDRLY”), and CHEECH & CHONG, LLC
EXCLUSIVE LICENSING AGREEMENT FOR BONFIGLIOLI TO MANUFACTURE AND SELL CVTCORP mCVT PATENTED TECHNOLOGYExclusive Licensing Agreement • October 9th, 2018
CVTCORP, a world leader in the design and development of revolutionary, high-efficiency mechanical Continuously Variable Transmissions (mCVT) for the off-highway market, and Bonfiglioli, a worldwide designer, manufacturer and distributor of a complete range of geared motors, drive systems, planetary gearboxes and inverters, announced they have entered into an exclusive licensing agreement for Bonfiglioli to manufacture and sell the CVTCORP mCVT patented technology for telehandlers and other equipment. The cooperation between Bonfiglioli and CVTCORP will also include developing a full line of transmissions based on the currently available mCVT.
Exclusive Licensing Agreement for “SONG NAME” DATE: NO DATEExclusive Licensing Agreement • February 24th, 2022 • Ontario
Kurate Music Ltd (“Label”) on behalf of its administered channel “Kurate Music is delighted to have this opportunity to work with Artist Name p/k/a: “performer name” collectively (“Artist”) to distribute and exploit certain sound recordings and audiovisual works owned or controlled by Artist as further detailed herein.
Medsenic partners with PhebraExclusive Licensing Agreement • July 8th, 2021
● Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases
Head of AgreementExclusive Licensing Agreement • January 23rd, 2021
ContractExclusive Licensing Agreement • April 30th, 2019
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
PSYENCE AND FILAMENT HEALTH ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR NATURAL PSILOCYBIN PRODUCTSExclusive Licensing Agreement • April 18th, 2022
Psyence is designing market-leading clinical trials in the field of palliative care, which will initially be conducted in the United Kingdom. The license grants Psyence exclusivity in the United Kingdom for the indications of anxiety and depression, and associated ailments, within the context of palliative care. Psyence intends to submit a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Exclusive Licensing Agreement LetterExclusive Licensing Agreement • March 2nd, 2009 • Constant Environment, Inc. • Ontario
Constant Environment, Inc. With Head Office at: 1310 Contour Drive, Mississauga, Ontario. Canada. L5H 1B2 (Hereafter referred to as LICENSEE)
English Translation) Exclusive Licensing Agreement For the Cultivation Technology of Cordyceps MilitarisExclusive Licensing Agreement • December 31st, 2008 • Yzapp International Inc • Services-computer programming, data processing, etc.
Definition: Cultivation technology of Cordyceps Militaris means the technical know-how for strains cultivation, cultivation techniques for any growth stage, processing method, picking, drying and finished goods packing of Cordyceps Militaris during the complete process.
EXCLUSIVE LICENSING AGREEMENT FOR IN-HOUSE DEVELOPED MONOCLONAL ANTIBODY FARLETUZUMAB IN LATIN AMERICA CONCLUDED WITH EUROFARMA LABORATÓRIOS S.A.Exclusive Licensing Agreement • September 9th, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its research subsidiary Morphotek, Inc. (Headquarters: Pennsylvania, United States, President and CEO: Nicholas Nicolaides, “Morphotek”) has signed an exclusive licensing agreement with Eurofarma Laboratórios S.A. (Headquarters: São Paulo, Brazil, President: Maurizio Billi, “Eurofarma”) to develop and commercialize the monoclonal antibody farletuzumab (development code: MORAb-003) as a potential anticancer agent in Latin America.
Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®Exclusive Licensing Agreement • August 18th, 2021
BAD VILBEL, Germany and LAVAL, Québec, Canada – August 18, 2021 – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, and STADA MENA DWC-LLC (“STADA”), a subsidiary of STADA Arzneimittel AG, a specialty pharma, generics and consumer healthcare group, today announced an exclusive commercialization and development license agreement (the “Agreement”) for the exclusive rights to the topical anaesthetic cream Pliaglis®, in 15 countries in the Middle East and North Africa (“MENA”) region, comprising: Saudi Arabia, the United Arab Emirates (“UAE”), Kuwait, Oman, Qatar, Bahrain, Jordan, Lebanon, Egypt, Algeria, Morocco, Tunisia, Iraq, Libya and Yemen (the “Territories”).
EUROPA GLOBAL, INC. EXCLUSIVE LICENSING AGREEMENT This exclusive licensing agreement ("Agreement") dated the 12th day of December, 2000 by and between Europa Global, Inc. (EGI), a Colorado corporation whose address is 102 S. Tejon Street, Suite 1100,...Exclusive Licensing Agreement • February 25th, 2002 • Maximum Dynamics Inc • Colorado
DanCann Pharma A/SRugvænget 5, Ansager 6823, DanmarkCompany reg. number: 3942 6005 E-mail: info@dancann.comExclusive Licensing Agreement • January 18th, 2021
DanCann Pharma’s strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor’s AKVANO® technology
Corporate Office: 35 South Ocean Avenue, Patchogue, New York, 11772 Phone: 1-888-488-6882 Fax: 1-888-265-0498Exclusive Licensing Agreement • February 21st, 2014 • Bravo Enterprises Ltd. • Crude petroleum & natural gas
Indian Institute of Food Processing TechnologyExclusive Licensing Agreement • February 15th, 2020
Exhibit 10.32 Exclusive Licensing Agreement ----------------------------- Whereas Longport, Inc. is the owner of the patent rights to a new medical technology which Longport calls the "soft tissue diagnostic scanner," developed in part by Dr. Mary...Exclusive Licensing Agreement • May 11th, 1998 • Longport Inc • Wholesale-medical, dental & hospital equipment & supplies
Translated from Chinese The Exclusive Licensing Agreement for Harbin Renhuang Pharmaceutical Co., Ltd. to Use Forest Resources under Yichun Red Star Forestry BureauExclusive Licensing Agreement • January 30th, 2012 • China Botanic Pharmaceutical • Pharmaceutical preparations
The exclusive licensing agreement to use forest resources under Yichun Red Star Forestry Bureau was signed by the following parties on January 11, 2011:
GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver DiseaseExclusive Licensing Agreement • September 27th, 2020
• Innovative multi-biomarker blood test based on GENFIT’S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (NASH)
Exclusive agreement with the Menarini Group, Berlin Chemie and Vectans Pharma for Sitavig® in Italy and Austria.Exclusive Licensing Agreement • March 9th, 2023
Menarini, Berlin Chemie and Vectans Pharma have signed an exclusive licensing agreement for the commercialization of Sitavig®50mg (Acyclovir Lauriad®), in Italy and Austria.
Exhibit 10.2 EXCLUSIVE LICENSING AGREEMENT This Exclusive Licensing Agreement ("Agreement") is made as of July 12, 2005 by and between Biowell Technology Inc., a company duly incorporated and organized under the laws of Taiwan, Republic of China...Exclusive Licensing Agreement • July 21st, 2005 • Applied Dna Sciences Inc • Biological products, (no disgnostic substances) • Nevada
BACHEM und Jitsubo have signed an exclusive licensing agreement for Jitsubo’s Molecular Hiving™ technology.Exclusive Licensing Agreement • March 2nd, 2021
The use of this technology allows for more environmentally friendly chemistry, reduced manufacturing costs and improved sustainabil- ity. Various projects for active pharmaceutical ingredients (APIs) as well as cosmetic peptides have already been initiated and success- fully realized with Jitsubo’s technology at Bachem.
